Client Result
Orrick Advises New Unicorn Unstoppable Domains on Series A Round
August.02.2022

August.02.2022
June.27.2022
The primary focus of the acquisition is on the lead medicine, Tazverik® (tazemetostat), a first-in-class, chemotherapy-free EZH2a inhibitor.
January.25.2022
January.20.2022
Orrick has advised Ford Next in the creation of Canopy, a joint venture with ADT Inc.
January.13.2022
October.20.2021
Orrick has advised Turn/River Capital on its investment in Invicti Security’s $625 million funding round, led by Summit Partners.
July.15.2021
June.25.2021
May.11.2021